Le Lézard
Classified in: Health
Subject: PARTNERSHIPS

NutraFuels, Inc. (NTFU) Forms Strategic Alliance with Hall Global To Manufacture, Market & Distribute Patented Alternative Delivery OTC Health and Wellness Products


COCONUT CREEK, FL--(Marketwired - May 09, 2017) - NutraFuels Inc. ("NutraFuels" or "NTFU"), (OTC PINK: NTFU), today announced that the company has executed a strategic alliance agreement with Hall Global and its partners to manufacture, market and distribute a multitude of unique and novel patented over the counter health and wellness products to be sold worldwide.

NTFU develops and manufactures products for the benefit of a number of daily health wellness uses that include; Sleep Support, Anti-Stress Relaxation, Energy & Focus, Cognitive Support, Weight-Loss and Pain Relief to name a few. The product formulations will be formulated with and without CBD (Cannibidiol) and packaged using Oral Sprays as well as the most advanced patented, optimal delivery systems available to the nutraceutical industry, i.e. Nutritional Drinking Straws and Blast Cap Drink Shots. These delivery methods allow for vitamins and nutrients to be absorbed efficiently and effectively in to the human body and are unique, convenient and economical for consumers. The products that the company produces will be packaged and marketed under a variety of brands and sold through multiple distribution channels such as; online, retail, direct response and affiliate networks.

Hall Global and its partners have expertise in creating products and brands with patented alternative delivery systems. Under this alliance, the products produced will be distributed through Hall Global's extensive worldwide network and partnerships. The products and brands produced will be marketed and sold on a revenue share basis between NTFU and Hall Global.

Also as part of the agreement, Hall Global's principle Michael R. Anderson will become NTFU's chief scientific advisor. Michael Anderson is a world-renowned inventor and holds many worldwide patents for metered dosing technology. Metered dosing technology is used throughout the pharmaceutical, nutraceutical and dietary supplement industry for its accuracy and metered delivery of drugs, vitamins and nutrients in to the human body.

"We are pleased to announce this strategic alliance between our two companies and Mr. Anderson," said Edgar Ward, Nutrafuels's CEO. "Hall Global and its partners bring a wealth of experience, knowledge, resources and relationships that we believe will be instrumental in the success of the products and brands we produce." As we move forward with additional new innovative formulas and products we remain focused on producing and distributing high quality daily health and wellness products to help improve the quality of life through naturally derived efficient and effective supplementation."

About NutraFuels, Inc.

NTFU was founded in 2010, to manufacture, distribute and market a line of oral spray nutritional dietary products to consumers, retailers and wholesale outlets. Oral spray delivery systems are recognized by many as an effective methodology for delivery of pharmaceutical and nutraceutical products. Oral spray delivery is recognized by consumers for its convenience, dosage precision and timely assimilation into the body. NTFU's product line consists of vitamins and nutrients in an aqueous solution, orally delivered through a non-aerosol pump. NTFU's products are sprayed into the mouth in the form of a fine mist entering the delicate tissue of the mouth. The nutrients are delivered into the bloodstream and assimilated throughout the body more quickly than traditional methods, avoiding the solubility and absorption problems common with most ingested vitamins and nutritional supplements in pill or capsule form.

Safe Harbor

This press release contains forward-looking statements, particularly as related to, among other things, the business plans of NutraFuels, Inc statements relating to goals, plans and projections regarding the NutraFuels' financial position and business strategy. The words or phrases "would be," "will allow," "intends to," "may result," "are expected to," "will continue," "anticipates," "expects," "estimate," "project," "indicate," "could," "potentially," "should," "believe," "think", "considers" or similar expressions are intended to identify "forward-looking statements." These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. NutraFuels cautions readers not to place undue reliance on such statements. NutraFuels does not undertake, and NutraFuels specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. Actual results may differ materially from NutraFuels' expectations and estimates.


These press releases may also interest you

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...



News published on and distributed by: